American Oncology Network Announces Research Studies to be Presented at ASCO 2026 Annual Meeting

Rhea-AI Summary

American Oncology Network (NASDAQ:AONC) announced that multiple research studies co-authored by its physicians and leaders were selected for presentation at the ASCO 2026 Annual Meeting, held May 29–June 2 in Chicago.

Topics span clinical trials, AI-driven registries, pharmacovigilance, health disparities, and large language model evaluation, underscoring AON’s role in community oncology research.

AON reports that its practices currently offer access to more than 150 clinical trials, bringing innovative treatment options to local communities.

Market Context

This announcement highlights American Oncology Network’s broad research engagement, with multiple ph...

Analysis

This announcement highlights American Oncology Network’s broad research engagement, with multiple physician-led studies accepted for the ASCO 2026 Annual Meeting and access to more than 150 clinical trials across its practices. Recent history shows continued expansion via new partners, physicians and conference participation, alongside affiliations offering over 500 trials. Investors may watch how this research presence supports patient recruitment, clinical innovation and practice growth, and whether future updates include concrete operational or financial metrics linked to these initiatives.

Key Figures

ASCO meeting dates: May 29–June 2, 2026 Clinical trials at AON: More than 150 clinical trials ASCO education hours: More than 145 hours +5 more

8 metrics

ASCO meeting dates May 29–June 2, 2026 ASCO 2026 Annual Meeting schedule

Clinical trials at AON More than 150 clinical trials Trials currently offered across AON practices

ASCO education hours More than 145 hours Annual meeting education, collaboration and research insights

OSUCCC–James trials More than 500 clinical trials Access via Zangmeister Cancer Center affiliation

Oncology Consultants locations 18 locations Practice footprint across South Texas

Medical oncologists 16 medical oncologists Oncology Consultants staffing

Radiation oncologists 3 radiation oncologists Oncology Consultants staffing

Daily price move -16.67% AONC price_change_24h_percent before this news

Historical Context

5 past events · Latest: May 21 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 21	Academic affiliation	Positive	+0.0%	Zangmeister Cancer Center affiliated with OSUCCC – James expanding trial access.
Apr 30	Physician hire	Positive	+2.8%	MidAmerica Cancer Care and AON welcomed Dr. Syed Karim to the network.
Apr 22	Conference participation	Positive	+16.1%	AON leaders scheduled for 11 sessions at COA 2026 conference.
Mar 05	Practice acquisition	Positive	-7.3%	Oncology Consultants joined AON, expanding trials and operational resources in South Texas.
Feb 04	Practice partnership	Positive	+4.3%	RKV Medical Center became AON’s first partner practice in Oklahoma.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive operational news has produced mixed reactions, with 3 aligned and 2 divergent price moves.

Recent Company History

Over the past six months, American Oncology Network has focused on expanding community oncology reach and visibility. Partnerships such as Zangmeister Cancer Center’s affiliation with OSUCCC – James added access to more than 500 clinical trials. The network welcomed new physicians and practices, including Oncology Consultants with 18 locations and multiple specialists, and RKV Medical Center as the first Oklahoma partner. Conference participation, including 11 sessions at the Community Oncology Alliance meeting, parallels today’s ASCO-related research presence, underscoring an ongoing emphasis on clinical research and education.

Key Terms

phase 3, antibody-drug conjugate, phase 2, pharmacovigilance, +4 more

8 terms

phase 3 medical

"A randomized, open-label, phase 3 study of ZL-1310, a DLL3 antibody-drug..."

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

antibody-drug conjugate medical

"ZL-1310, a DLL3 antibody-drug conjugate (ADC), compared to investigator’s..."

An antibody-drug conjugate is a targeted medicine that combines an antibody, which can identify specific cells, with a powerful drug designed to destroy those cells. This approach allows for precise treatment, minimizing damage to healthy tissue. For investors, developments in this area can signal advances in cancer therapies and potential growth opportunities in the biotech sector.

phase 2 medical

"EPCORE NHL-6: Phase 2 study of subcutaneous (SC) epcoritamab as outpatient..."

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

pharmacovigilance medical

"Shajadi Patan, MD, of MidAmerica Cancer Care, contributed to several pharmacovigilance..."

Pharmacovigilance is the process of monitoring and assessing the safety of medicines after they are on the market, ensuring that any side effects or risks are identified and managed. For investors, it matters because it helps ensure that pharmaceutical companies maintain safe products, which can influence a company’s reputation, regulatory approval, and financial stability over time.

real-world evidence medical

"contributed to several pharmacovigilance and real-world evidence studies, including:"

Real-world evidence is information gathered from everyday sources like patient records, insurance claims, or everyday experiences, rather than controlled experiments or clinical trials. It helps investors understand how products or policies perform in real life, providing a more complete picture of their effectiveness and value beyond official tests. This type of evidence can influence decision-making by offering insights based on actual, everyday outcomes.

meta-analysis medical

"stage I triple-negative breast cancer: A systematic review and meta-analysis..."

A meta-analysis combines results from multiple independent studies on the same question to produce a single, more reliable estimate of an effect or outcome. Like averaging many temperature readings to get a truer picture of the weather, it reduces random noise and highlights consistent signals; investors use it to assess how strong and reliable the scientific or economic evidence is, which affects regulatory outlook, product prospects, and valuation risk.

randomized controlled trials medical

"breast cancer: A systematic review and meta-analysis of randomized controlled trials."

Randomized controlled trials are studies where participants are randomly assigned to receive either a new treatment or a comparison (such as a standard treatment or placebo), so outcomes can be fairly compared like flipping a coin to decide teams. For investors, they matter because they provide the most reliable evidence about whether a drug, device or intervention actually works and is safe, which influences regulatory approval, market demand and the financial outlook of companies developing them.

large language models technical

"Benchmarking next-generation large language models (LLMS): Evaluation of patient-oriented..."

Large language models are advanced AI systems trained on vast amounts of text to understand and generate human-like writing, like a very fast reader and writer that learns patterns in words and sentences. They matter to investors because they can change how companies operate—automating customer service, speeding analysis, cutting costs, creating new products—and they introduce risks around accuracy, security and regulation that can affect a firm’s revenue and reputation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Several AON physicians and leaders sharing new cancer research at one of oncology’s most influential gatherings

FORT MYERS, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- American Oncology Network (AON), one of the nation’s fastest-growing networks of community oncology practices, is pleased to announce that multiple research studies co-authored by AON physicians and leaders have been selected for presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, being held May 29-June 2 in Chicago.

The following abstracts were accepted after a rigorous review process and will be presented through poster discussions, oral presentations or online publication:

• Ruemu Ejedafeta Birhiray, MD, of Hematology Oncology of Indiana, co-authored the following studies:
  • Recognizing the inequities in oncology research and clinical practice guidelines—An analysis of clinical guidelines in multiple myeloma.
  • A review of representation in clinical trials for metastatic prostate carcinoma.
    
    
• Ralph V. Boccia, MD, FACP, of The Center for Cancer and Blood Disorders (CCBD), co-authored the following studies:
  
  
  • A randomized, open-label, phase 3 study of ZL-1310, a DLL3 antibody-drug conjugate (ADC), compared to investigator’s choice therapy in participants with relapsed small cell lung cancer. (DLLEVATE)
  • EPCORE NHL-6: Phase 2 study of subcutaneous (SC) epcoritamab as outpatient treatment for 2L+ relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
    
    
• Luis T. Campos, MD, of Oncology Consultants, co- authored An AI-powered, human-in-the-loop, real-time registry platform to enable clinical trials, pragmatic studies, and prospective external control arms (ProECA) at scale in US community practices.
  
  
• Shajadi Patan, MD, of MidAmerica Cancer Care, contributed to several pharmacovigilance and real-world evidence studies, including:
  
  
  • Sociodemographic disparities in sepsis-associated mortality among patients with gastrointestinal malignancies in the United States.
  • Machine learning–based projections of cancer and depression mortality in the United States through 2035.
  • The effect of adjuvant carboplatin-based chemotherapy in stage I triple-negative breast cancer: A systematic review and meta-analysis of randomized controlled trials.
  • Benchmarking next-generation large language models (LLMS): Evaluation of patient-oriented prostate cancer guidance.
  • Mortality trends and disparities in prostate cancer with co-occurring cardiometabolic disorders among U.S. men aged ≥ 55 years, 1999–2024.
  • Inequities in breast cancer mortality with contributing cardiometabolic disorders among U.S. women aged ≥45 years, 1999–2024.
  • Evaluating reliability of large language models for patient queries: Concordance with NCCN invasive breast cancer guideline using ChatGPT, DeepSeek, and Gemini.

• Julio A. Peguero, MD, of Oncology Consultants, co-authored Impact of eftilagimod alfa, an APC activator via MHC class II, on lymphocyte activation and survival outcomes in metastatic cancer patients.
  

“It is a privilege to share our research and latest findings with colleagues at ASCO,” said Dr. Boccia, who also serves as medical director of CCBD and research for AON. “The meeting encourages collaboration, innovation and continued progress in clinical oncology. Our participation reflects AON’s commitment to advancing evidence-based cancer care.”

“Oncology research is not only about identifying new treatments, but also about expanding our understanding of cancer itself,” said Dr. Stephen “Fred” Divers, AON’s chief medical officer. “Every study helps move us closer to more precise care, improved outcomes and, ultimately, a cure. We are proud to contribute to that important work.”

“The strong presence of our physicians and leaders at ASCO reflects the exceptional talent across our network,” said Todd Schonherz, AON’s chief executive officer. “We are proud to support research efforts that advance oncology care while reinforcing AON’s culture of innovation, collaboration and continuous learning.”

ASCO is one of the leading professional organizations for oncology professionals, offering more than 145 hours of education, collaboration and research insights each year during its annual meeting.

AON has numerous practices actively participating in clinical research. Currently, AON practices offer access to more than 150 clinical trials, making cutting-edge treatment options available within local communities.

For more information about AON, visit www.AONcology.com.

About American Oncology Network
American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 350 providers practicing across 21 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. For more information, please visit AONcology.com or follow us on LinkedIn, Facebook, X (formerly Twitter) and YouTube.

Media Contact:
Karen Riley Sawyer
American Oncology Network
Karen.Sawyer@AONcology.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fd460573-014c-4f7c-809d-d26caa3f8afe

FAQ

What did American Oncology Network (AONC) announce about ASCO 2026 presentations?

American Oncology Network announced that multiple co-authored research studies were accepted for presentation at ASCO 2026. According to American Oncology Network, these works cover clinical trials, real-world evidence, AI tools, and health disparities in cancer care across several tumor types.

Which key research areas will AONC-affiliated physicians present at ASCO 2026?

AONC-affiliated physicians will present research on clinical trials, inequities, pharmacovigilance, AI platforms, and large language models. According to American Oncology Network, topics include small cell lung cancer, DLBCL, breast and prostate cancer, cardiometabolic comorbidities, and machine learning–based mortality projections.

How is American Oncology Network (AONC) involved in clinical trials as of May 2026?

American Oncology Network reports that its practices currently offer access to more than 150 clinical trials. According to American Oncology Network, this network brings cutting-edge treatment options into local community oncology settings, expanding access beyond major academic centers.

What AI and large language model studies linked to AONC are featured at ASCO 2026?

AONC-linked studies at ASCO 2026 include AI-powered registries and benchmarking large language models. According to American Oncology Network, research evaluates AI-enabled real-time trial platforms and tests LLM reliability for patient-oriented prostate and breast cancer guidance versus established NCCN guidelines.

Which AONC physicians are named as co-authors on ASCO 2026 research abstracts?

Named AONC-affiliated co-authors include Drs. Ruemu Ejedafeta Birhiray, Ralph V. Boccia, Luis T. Campos, Shajadi Patan, and Julio A. Peguero. According to American Oncology Network, these physicians contribute across clinical trials, inequities research, AI tools, and immunotherapy-related outcomes.

What does AONC highlight about ASCO 2026’s importance for oncology professionals?

American Oncology Network highlights ASCO as a leading oncology meeting offering extensive education and collaboration. According to American Oncology Network, the annual meeting provides more than 145 hours of sessions and fosters innovation, evidence-based practice, and progress in clinical oncology for participating professionals.